Back to top
more

Exelixis (EXEL)

(Delayed Data from NSDQ)

$22.40 USD

22.40
1,189,759

-0.15 (-0.67%)

Updated Jul 12, 2024 04:00 PM ET

After-Market: $22.41 +0.01 (0.04%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth B Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (75 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Puma & Medison Team Up to Commercialize Nerlynx in Israel

by Zacks Equity Research

Puma (PBYI) and Medison enters into a licensing deal to commercialize Puma's breast cancer treatment drug Nerlynx in Israel.

    What's in the Cards for GW Pharma (GWPH) in Q1 Earnings?

    by Zacks Equity Research

    GW Pharma (GWPH) will report fiscal first-quarter results next week. Investors focus is expected to be on the Epidiolex commercialization plan.

      Debapriya Chakraborty headshot

      Theravance's NDA for COPD Candidate Gets FDA Acceptance

      by Debapriya Chakraborty

      The FDA accepts the new drug application for Theravance (TBPH) and partner Mylan's COPD candidate, revefenacin. A response on the same is expected on Nov 13, 2018.

        Roche Gets Breakthrough Therapy Designation For ASD Drug

        by Zacks Equity Research

        Roche obtains Breakthrough Therapy Designation for its experimental drug oral medicine balovaptan from the FDA which is likely to expedite the review and development of the drug.

          Vertex (VRTX) to Report Q4 Earnings: What's in the Cards?

          by Zacks Equity Research

          Vertex Pharmaceuticals (VRTX) will report its Q4 results on Jan 31, 2018.

            Glaxo's Shingles Vaccine Shingrix Gets Positive CHMP Opinion

            by Zacks Equity Research

            The Committee for Medicinal Products for Human Use passes a positive viewpoint on Glaxo's (GSK) shingles vaccine, Shingrix. A final decision from the EU is awaited in April 2018.

              Quality Systems (QSII) Q3 Earnings in Line, Revenues Beat

              by Zacks Equity Research

              Quality Systems (QSII) benefits from solid bookings and acquisitions in Q3.

                Vertex (VRTX) Stock Up 70% in a Year's Time: Here's Why

                by Zacks Equity Research

                Vertex Pharmaceuticals' (VRTX) stock rallies on consistent expansion in patient population through label expansions of Kalydeco and Orkambi and positive data readout from pivotal studies.

                  Dr. Reddy's (RDY) Q3 Earnings Fall, Revenues Improve Y/Y

                  by Zacks Equity Research

                  Dr. Reddy's (RDY) earnings per American Depositary Share were down 27.3% in third-quarter fiscal 2018 from the year-ago quarter while the top line beat the prior-year figure.

                    Shire Gets FDA Nod for Cinryze Tech Transfer to New Site

                    by Zacks Equity Research

                    Shire (SHPG) receives an FDA approval for transferring the product manufacturing technology of its hereditary angioedema drug, Cinryze, to its manufacturing site in Vienna, Austria.

                      EU Unlikely to Approve Puma's Nerlynx in 2018, Stock Down

                      by Zacks Equity Research

                      Puma's (PBYI) shares decline after CHMP conveyed the company that the former will probably vote against the approval of breast cancer drug Nerlynx at the CHMP meeting scheduled in February.

                        The Zacks Analyst Blog Highlights: Anthera Pharmaceuticals, Bio-Techne, Exelixis, Paratek and Bioverativ

                        by Zacks Equity Research

                        The Zacks Analyst Blog Highlights: Anthera Pharmaceuticals, Bio-Techne, Exelixis, Paratek and Bioverativ

                          Novartis Announces Positive Results on Migraine Candidate

                          by Zacks Equity Research

                          Novartis announced positive results on migraine candidate, AMG334, from the phase IIIb study. The candidate is being developed in collaboration with Amgen,

                            Anthera's Sollpura Strong on Positive Futility in Phase III

                            by Zacks Equity Research

                            Anthera (ANTH) posts positive results from the second interim futility analysis of Sollpura for EPI. Top-line data from the study is expected in the first quarter of 2018.

                              Seattle Genetics' Adcetris Gets EU Nod for Label Expansion

                              by Zacks Equity Research

                              European Commission extend the current conditional marketing authorization for an expanded indication of Adectris of Seattle Genetics (SGEN) and partner Takeda.

                                Regeneron's Dupixent Receives MHLW Nod for Label Expansion

                                by Zacks Equity Research

                                Ministry of Health, Labor and Welfare (MHLW) in Japan has granted approval for the label expansion of Regeneron's (REGN) Dupixent.

                                  BioCryst (BCRX) & Idera (IDRA) Announce Merger, Shares Fall

                                  by Zacks Equity Research

                                  Shares of BioCryst Pharmaceuticals (BCRX) and Idera Pharmaceuticals (IDRA) plunge following the announcement of their merger.

                                    Tirthankar Chakraborty headshot

                                    Fancy Biotech Stocks on Buyout Buzz? 5 Top Picks

                                    by Tirthankar Chakraborty

                                    More deals are expected to be signed in the biotech space, now that the tax reform bill allows companies to repatriate cash pilling up overseas.

                                      Bristol-Myers (BMY) Reports Data from CheckMate-142 Study

                                      by Zacks Equity Research

                                      Bristol-Myers (BMY) announces new data from a cohort of the phase II CheckMate -142 study evaluating Opdivo (nivolumab) and Yervoy (ipilimumab).

                                        Here's Why Agios (AGIO) Stock is Up More Than 50% in a Year

                                        by Zacks Equity Research

                                        Last year's FDA approval of Agios' (AGIO) only marketed drug Idhifa and its rapid progress on a robust pipeline during the period drive the share price consistently.

                                          BeiGene (BGNE) Surges: Stock Moves 12.6% Higher

                                          by Zacks Equity Research

                                          BeiGene (BGNE) saw a big move last session, as its shares jumped nearly 13% on the day, amid huge volumes.

                                            BioLineRx Cancer Drug Positive as Monotherapy in Phase IIa

                                            by Zacks Equity Research

                                            BioLineRx (BLRX) posts encouraging partial results from the monotherapy portion of a phase IIa COMBAT study, assessing its lead pipeline candidate, BL-8040, for pancreatic cancer patients.

                                              Merck Strong on Confirmatory Phase III Lung Cancer Study

                                              by Zacks Equity Research

                                              Merck's (MRK) Keytruda in combination with Eli Lilly's Alimta and carboplatin meet dual primary endpoints in a confirmatory phase III study for the first-line treatment of lung cancer.

                                                Novo Nordisk's (NVO) Hits 52-Week High: What's Driving It?

                                                by Zacks Equity Research

                                                Regulatory approvals of some key pipeline candidates along with the strong performance of products like Victoza have contributed to a rally in Novo Nordisk's (NVO) shares.

                                                  Exelixis, Ipsen Report Positive Results on Lead Cancer Drug

                                                  by Zacks Equity Research

                                                  Exelixis (EXEL) and Ipsen announce detailed results from the late stage study of lead drug Cabometyx in patients with previously treated advanced HCC.